SELLAS Life Sciences Group, Inc. (SLS) Stock Analysis — Probabli.AI
AI-powered analysis for SLS (SELLAS Life Sciences Group, Inc.): probabilistic price forecasts, technical signals, peer comparison, institutional ownership, earnings history, and social sentiment. Latest AI outlook: Bullish.
Last price: $5.96 · Market cap: $921.2M · AI outlook: Bullish
SELLAS Life Sciences Group Inc., a biopharmaceutical company traded on the NCM exchange, is a speculative yet promising investment driven by its innovative approaches in oncology. Recent headlining advancements, equity strength, and strong analyst sentiment present an attractive short-term opportunity, although clinical delays and inherent risks underline the necessity of caution. Long-term…
Probabilistic 1-Year Outlook
- Bull 60% · Neutral 30% · Bear 10%
- 1-year price estimates — P10: $5 / P50: $7 / P90: $9
- The bullish outlook is based on recent positive data from phase 2 trials and equity financing to advance clinical trials. The analyst consensus being a strong buy with a mean target of $7.00 suggests bullish sentiment.…
5-Year Outlook
- Bull 70% · Neutral 20% · Bear 10%
- 5-year price estimates — P10: $7 / P50: $15 / P90: $23
SWOT Highlights
- Strength: Strong clinical trial results in phase 2
- Strength: Supportive equity financing setup
- Risk: Clinical trial delays
- Risk: Currently unprofitable
Major Catalysts
- [object Object]
- [object Object]
- [object Object]
Analyst Coverage & Dividends
1 Wall Street analyst rate SLS a STRONG BUY with a mean price target of $7.
Last analyzed · Model: gpt-4o. How this forecast works · Accuracy & validation.
SLS forecast details · SLS sentiment details · SLS insider activity
Recent saved forecast research
AI-generated research records, not evaluated investment results.
- SELLAS Life Sciences Group, Inc. (SLS) — saved
SELLAS Life Sciences Group Inc., a biopharmaceutical company traded on the NCM exchange, is a speculative yet promising investment driven by its innovative approaches in oncology. Recent headlining advancements, equity strength, and strong
- SELLAS Life Sciences Group, Inc. (SLS) — saved
SELLAS Life Sciences Group, Inc. (SLS) presents a compelling investment opportunity due to its strong clinical progress, frequent EPS beats, and favorable analyst outlook. Despite certain operational challenges, its potential for breakthrou
The information on this page is for educational and informational purposes only and does not constitute professional financial advice.